Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Real-time Estimate Cboe BZX  -  04:10 2022-09-28 pm EDT
166.18 USD   +0.75%
01:00pTrending : Johnson & Johnson's New Band-Aid, Tylenol Company to Be Named Kenvue
DJ
09:46aJohnson & Johnson : Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
PU
08:35aJohnson & Johnson Says Planned Consumer Health Company to Be Named Kenvue
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

08/09/2022 | 04:34pm EDT

Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, at the Sheraton New York Hotel in New York. Joaquin Duato, Chief Executive Officer, and Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48-hrs after the webcast.


© Business Wire 2022
All news about JOHNSON & JOHNSON
01:00pTrending : Johnson & Johnson's New Band-Aid, Tylenol Company to Be Named Kenvue
DJ
09:46aJohnson & Johnson : Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the L..
PU
08:35aJohnson & Johnson Says Planned Consumer Health Company to Be Named Kenvue
MT
07:46aJohnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
BU
09/27Legend Biotech's Cancer Drug Carvykti Gets Japanese Approval to Treat Certain Adults wi..
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM
AQ
09/22Over 200 Inmates, Prison Officers Vaccinated Against Covid-19
AQ
09/21J&J's talc Texas two-step called out by victims
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 525 M - -
Net income 2022 22 023 M - -
Net cash 2022 9 791 M - -
P/E ratio 2022 20,2x
Yield 2022 2,65%
Capitalization 434 B 434 B -
EV / Sales 2022 4,44x
EV / Sales 2023 4,16x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 164,94 $
Average target price 185,07 $
Spread / Average Target 12,2%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-3.58%433 657
ELI LILLY AND COMPANY11.32%295 599
ROCHE HOLDING AG-17.54%259 622
ABBVIE INC.4.67%250 575
PFIZER, INC.-25.33%247 449
NOVO NORDISK A/S1.63%218 252